There are 2867 resources available
1312O - From regulating off-label use to creating an environment for drug repurposing in oncology
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Proffered Paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
784O - Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial
Presenter: Dirk Schadendorf
Session: Proffered Paper session 1: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
617O - Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results
Presenter: Chunkang Chang
Session: Proffered Paper session: Haematological malignancies
Resources:
Abstract
Slides
Webcast
LBA18 - Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial
Presenter: Fabrice André
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA61 - HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC)
Presenter: Liwei Wang
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
Defining the role of the pathologist in the era of Next Generation Sequencing
Presenter: Giancarlo Pruneri
Session: Elements to build a Molecular Tumour Board
Resources:
Slides
Webcast
Cervical cancer
Presenter: Ana Oaknin
Session: Is immunotherapy changing the standard of care in gynaecological cancers?
Resources:
Slides
Webcast
Invited Discussant 617O
Presenter: Thomas Cluzeau
Session: Proffered Paper session: Haematological malignancies
Resources:
Slides
Webcast
730MO - First-in-human phase I study of INCAGN02390, a TIM-3 monoclonal antibody antagonist in patients with advanced malignancies
Presenter: Martin Gutierrez
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1313O - Assessment of investigational new drugs (INDs) approved in USA and Europe after early phase trials using the ESMO-magnitude of clinical benefit scale (ESMO-MCBS)
Presenter: Justin Moyers
Session: Proffered Paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast